Related Content
Search Google Scholar for:
|
J. Biol. Chem. 275 (25): 19159-19166
© 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Mildly Oxidized Low Density Lipoprotein Rapidly Stimulates via
Activation of the Lysophosphatidic Acid Receptor Src Family and Syk
Tyrosine Kinases and Ca2+ Influx in Human Platelets*
Petra
Maschberger ,
Markus
Bauer ,
Jutta
Baumann-Siemons ,
Konrad J.
Zangl ,
Emil V.
Negrescu §,
Armin J.
Reininger¶ , and
Wolfgang
Siess **
From the Institut für Prophylaxe und
Epidemiologie der Kreislaufkrankheiten, Universität
München, Pettenkoferstrasse P, D-80336 München, Germany and
¶ Institut für Anatomie, Technische Universität
München, Biedersteiner Strasse 29, D-80802 München, Germany
In contrast to native low density lipoprotein
(LDL), mildly oxidized LDL (mox-LDL) induced platelet shape change and
stimulated during shape change the tyrosine phosphorylation of specific
proteins including Syk; the translocation of Src, Fyn, and Syk to the
cytoskeleton; and the increase of cytosolic Ca2+ due
to mainly Ca2+ entry. The stimulation of these early signal
pathways by mox-LDL was inhibited by desensitization of the
lysophosphatidic acid (LPA) receptor and specific LPA receptor
antagonists, was independent of the
IIb 3-integrin, and was mimicked by LPA.
Stimulation of tyrosine phosphorylation and Syk activation were
independent of the increase of cytosolic Ca2+ and were
suppressed by genistein and two specific inhibitors of the Src family
tyrosine kinases, PP1 and PD173956. In contrast to PP1 and PD 173956, genistein prevented shape change by mox-LDL. The results indicate that
mox-LDL, through activation of the LPA receptor, stimulates two
separate early signal pathways, (a) Src family and Syk
tyrosine kinases, and (b) Ca2+ entry. The
activation of these early signaling pathways by mox-LDL probably plays
a role in platelet responses subsequent to shape change. The inhibition
of mox-LDL-induced platelet activation by LPA receptor antagonists or
dietary isoflavonoids such as genistein could have implications in the
prevention and therapy of cardiovascular diseases.
*
This work was supported by the Ernst und Berta
Grimmke-Stiftung, Deutsche Forschungsgemeinschaft Grants Si 274 6-1
and GRK 438, and the August-Lenz-Stiftung. This work is submitted in
partial fulfillment of thesis requirements for P. M., M. B.,
J. B.-S., and K. J. Z. at the University of Munich.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Molecular Cardiology, Joseph J. Jacobs
Center for Thrombosis and Vascular Biology, The Cleveland Clinic
Foundation, Cleveland, OH 44195.
Present address: The Scripps Research Institute, Department of
Molecular and Experimental Medicine, La Jolla, CA 92037.
**
To whom correspondence should be addressed: Institut für
Prophylaxe und Epidemiologie der Kreislaufkrankheiten, Klinikum Innenstadt, Universität München, Pettenkoferstr. 9, D-80336 München, Germany. Tel.: 49-89-5160-4380; Fax: 49-89-5160-4382; E-mail: wolfgang.siess@klp.med.uni-muenchen.de.
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein.
- K. Chen, M. Febbraio, W. Li, and R. L. Silverstein (2008)
Circ. Res.
102, 1512-1519
| Abstract »
| Full Text »
| PDF »
- Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis.
- D. Siegel-Axel, K. Daub, P. Seizer, S. Lindemann, and M. Gawaz (2008)
Cardiovasc Res
78, 8-17
| Abstract »
| Full Text »
| PDF »
- Platelet Activation by Oxidized Low Density Lipoprotein Is Mediated by Cd36 and Scavenger Receptor-A.
- S. J.A. Korporaal, M. Van Eck, J. Adelmeijer, M. Ijsseldijk, R. Out, T. Lisman, P. J. Lenting, T. J.C. Van Berkel, and J.-W. N. Akkerman (2007)
Arterioscler. Thromb. Vasc. Biol.
27, 2476-2483
| Abstract »
| Full Text »
| PDF »
- Effect of Oxidation on the Platelet-Activating Properties of Low-Density Lipoprotein.
- S. J.A. Korporaal, G. Gorter, H. J.M. van Rijn, and J.-W. N. Akkerman (2005)
Arterioscler. Thromb. Vasc. Biol.
25, 867-872
| Abstract »
| Full Text »
| PDF »
- Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-{kappa}B-dependent mechanism.
- H. Lee, C. I. Lin, J.-J. Liao, Y.-W. Lee, H. Y. Yang, C.-Y. Lee, H.-Y. Hsu, and H. L. Wu (2004)
Am J Physiol Cell Physiol
287, C1657-C1666
| Abstract »
| Full Text »
| PDF »
- Cbl-mediated Degradation of Lyn and Fyn Induced by Constitutive Fibroblast Growth Factor Receptor-2 Activation Supports Osteoblast Differentiation.
- K. Kaabeche, J. Lemonnier, S. Le Mee, J. Caverzasio, and P. J. Marie (2004)
J. Biol. Chem.
279, 36259-36267
| Abstract »
| Full Text »
| PDF »
- LDL oxidized by hypochlorous acid causes irreversible platelet aggregation when combined with low levels of ADP, thrombin, epinephrine, or macrophage-derived chemokine (CCL22).
- L. G. Coleman Jr, R. K. Polanowska-Grabowska, M. Marcinkiewicz, and A. R. L. Gear (2004)
Blood
104, 380-389
| Abstract »
| Full Text »
| PDF »
- Modification of LDL with human secretory phospholipase A2 or sphingomyelinase promotes its arachidonic acid-releasing propensity.
- J. Oestvang, D. Bonnefont-Rousselot, E. Ninio, J. K. Hakala, B. Johansen, and M. W. Anthonsen (2004)
J. Lipid Res.
45, 831-838
| Abstract »
| Full Text »
| PDF »
- The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors.
- N. Haseruck, W. Erl, D. Pandey, G. Tigyi, P. Ohlmann, C. Ravanat, C. Gachet, and W. Siess (2004)
Blood
103, 2585-2592
| Abstract »
| Full Text »
| PDF »
- Lysophosphatidic Acid (LPA) in Malignant Ascites Stimulates Motility of Human Pancreatic Cancer Cells through LPA1.
- T. Yamada, K. Sato, M. Komachi, E. Malchinkhuu, M. Tobo, T. Kimura, A. Kuwabara, Y. Yanagita, T. Ikeya, Y. Tanahashi, et al. (2004)
J. Biol. Chem.
279, 6595-6605
| Abstract »
| Full Text »
| PDF »
- Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors.
- H. Ohta, K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, et al. (2003)
Mol. Pharmacol.
64, 994-1005
| Abstract »
| Full Text »
| PDF »
- Subtype-Selective Antagonists of Lysophosphatidic Acid Receptors Inhibit Platelet Activation Triggered by the Lipid Core of Atherosclerotic Plaques.
- E. Rother, R. Brandl, D. L. Baker, P. Goyal, H. Gebhard, G. Tigyi, and W. Siess (2003)
Circulation
108, 741-747
| Abstract »
| Full Text »
| PDF »
- LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression.
- P. E. Coy, N. Taneja, I. Lee, C. Hecquet, J. M. Bryson, and R. B. Robey (2002)
Am J Physiol Renal Physiol
283, F271-F279
| Abstract »
| Full Text »
| PDF »
- Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia.
- C. D. Garlichs, S. John, A. Schmei{beta}er, S. Eskafi, C. Stumpf, M. Karl, M. Goppelt-Struebe, R. Schmieder, and W. G. Daniel (2001)
Circulation
104, 2395-2400
| Abstract »
| Full Text »
| PDF »
- Hematopoietic reconstitution of SLP-76 corrects hemostasis and platelet signaling through alpha IIbbeta 3 and collagen receptors.
- B. A. Judd, P. S. Myung, L. Leng, A. Obergfell, W. S. Pear, S. J. Shattil, and G. A. Koretzky (2000)
PNAS
97, 12056-12061
| Abstract »
| Full Text »
| PDF »
|
|